Financial_NN
Statements_NOMZ
97_CD
8_CD
INTANGIBLE_NN
ASSETS_NN
Product_NN
marketing_GER
and_PHC
Software_NN
distribution_NOMZ
Other_JJ
development_NOMZ
Goodwill_NN
rights_NN
intangibles_VPRT
costs_NN
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cost_NN
At_PIN
1_CD
January_NN
2003_CD
1,254_CD
2,537_CD
398_CD
352_CD
4,541_CD
Additions_NOMZ
-_:
separately_RB
acquired_VBN
1_CD
38_CD
32_CD
61_CD
132_CD
Additions_NOMZ
-_:
internally_RB
developed_VBN
43_CD
43_CD
Exchange_NN
and_CC
other_JJ
movements_NOMZ
52_CD
382_CD
5_CD
6_CD
445_CD
At_PIN
31_CD
December_NN
2003_CD
1,307_CD
2,957_CD
435_CD
462_CD
5,161_CD
Additions_NOMZ
separately_RB
acquired_VBD
42_CD
40_CD
74_CD
156_CD
Additions_NOMZ
internally_RB
developed_VBD
59_CD
59_CD
Exchange_NN
and_CC
other_JJ
movements_NOMZ
18_CD
203_CD
2_CD
1_CD
224_CD
At_PIN
31_CD
December_NN
2004_CD
1,325_CD
3,202_CD
477_CD
596_CD
5,600_CD
Additions_NOMZ
separately_RB
acquired_VBD
43_CD
57_CD
76_CD
176_CD
Additions_NOMZ
internally_RB
developed_VBD
Exchange_NN
and_CC
other_JJ
movements_NOMZ
45_CD
442_CD
31_CD
23_CD
541_CD
At_PIN
31_CD
December_NN
2005_CD
1,280_CD
2,803_CD
503_CD
649_CD
5,235_CD
Amortisation_NOMZ
and_PHC
impairment_NOMZ
losses_NN
At_PIN
1_CD
January_NN
2003 310 827 275_CD
242_CD
1,654_CD
Amortisation_NOMZ
for_PIN
the_DT
year_NN
204_CD
28_CD
64_CD
296_CD
Impairment_NOMZ
charge_NN
7_CD
7_CD
Exchange_NN
and_CC
other_JJ
movements_NOMZ
14_CD
155_CD
8_CD
177_CD
At_PIN
31_CD
December_NN
2003_CD
324_CD
1,186_CD
318_CD
306_CD
2,134_CD
Amortisation_NOMZ
for_PIN
year_NN
220_CD
25_CD
61_CD
306_CD
Impairment_NOMZ
charge_NN
10_CD
10_CD
Exchange_NN
and_CC
other_JJ
movements_NOMZ
2_CD
101_CD
8_CD
5_CD
100_CD
At_PIN
31_CD
December_NN
2004_CD
336_CD
1,507_CD
335_CD
372_CD
2,550_CD
Amortisation_NOMZ
for_PIN
year_NN
214_CD
19_CD
39_CD
272_CD
Exchange_NN
and_CC
other_JJ
movements_NOMZ
9_CD
288_CD
3_CD
5_CD
299_CD
At_PIN
31_CD
December_NN
2005_CD
327_CD
1,433_CD
357_CD
406_CD
2,523_CD
Net_JJ
book_NN
value_NN
At_PIN
31_CD
December_NN
2003_CD
983_CD
1,771_CD
117_CD
156_CD
3,027_CD
At_PIN
31_CD
December_NN
2004_CD
989_CD
1,695_CD
142_CD
224_CD
3,050_CD
At_PIN
31_CD
December_NN
2005_CD
953_CD
1,370_CD
146_CD
243_CD
2,712_CD
Amortisation_NOMZ
and_PHC
impairment_NOMZ
charges_NN
Amortisation_NOMZ
and_PHC
impairment_NOMZ
charges_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
The_DT
impairment_NOMZ
in_PIN
2004_CD
was_VBD [BEMA]
in_PIN
relation_NOMZ
to_PIN
the_DT
write-off_PIN
of_PIN
goodwill_NN
associated_VBN [WZPAST]
with_PIN
Exanta_NN
._.
The_DT
impairment_NOMZ
in_PIN
2003_CD
was_VBD [BEMA]
in_PIN
respect_NN
of_PIN
amounts_NN
capitalized_VBN [WZPAST]
in_PIN
relation_NOMZ
to_PIN
collaboration_NOMZ
arrangements_NOMZ
with_PIN
NicOx_NN
and_CC
in_PIN
respect_NN
of_PIN
ANG453_NN
,_,
which_WDT [SERE]
were_VBD [PASS]
terminated_VBN
._.
For_PIN
the_DT
purposes_NN
of_PIN
impairment_NOMZ
testing_GER
of_PIN
goodwill_NN
,_,
the_DT
Group_NN
is_VPRT [PASS]
regarded_VBN
as_IN
a_DT
single_JJ
,_,
cash-generating_JJ
unit_NN
._.
The_DT
cash-generating_JJ
units_NN
recoverable_JJ
amount_NN
is_VPRT [PASS]
based_VBN
on_PIN
value_NN
in_PIN
use_NN
using_VBG [WZPRES]
projections_NOMZ
of_PIN
the_DT
Groups_NN
performance_NN
over_IN
ten_CD
years_NN
,_,
a_DT
period_NN
reflecting_VBG [PRIV] [WZPRES]
the_DT
patent-protected_JJ
lives_NN
of_PIN
our_FPP1
current_JJ
products_NN
._.
A_DT
risk-adjusted_JJ
discount_NN
rate_NN
of_PIN
12_CD
%_NN
has_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
to_PIN
the_DT
projections_NOMZ
._.
Material_NN
assets_NN
Carrying_VBG [WZPRES]
Remaining_VBG
value_NN
amortisation_NOMZ
Description_NOMZ
$_$
m_JJ
period_NN
Goodwill_NN
in_PIN
the_DT
US_FPP1
Goodwill_NN
707_CD
Not_XX0
amortised_JJ
Intangible_JJ
assets_NN
arising_VBG [WZPRES]
from_PIN
joint_JJ
venture_NN
with_PIN
Merck_NN
Product_NN
,_,
marketing_GER
and_PHC
distribution_NOMZ
rights_NN
368_CD
8_CD
and_CC
12_CD
years_NN
Advance_NN
payment_NOMZ
Product_NN
,_,
marketing_GER
and_PHC
distribution_NOMZ
rights_NN
668_CD
13_CD
years_NN
These_DEMO
assets_NN
are_VPRT [PASS]
associated_VBN
with_PIN
the_DT
restructuring_GER
of_PIN
the_DT
joint_JJ
venture_NN
with_PIN
Merck_NN
&_CC
Co._NN
._.
Inc._NN
._.
